Capsida Biotherapeutics, Inc.
Clinical trials sponsored by Capsida Biotherapeutics, Inc., explained in plain language.
-
Gene therapy trial hopes to slow Parkinson's in people with GBA1 mutation
Disease control TerminatedThis early-stage trial tests a single dose of CAP-003 gene therapy in 31 adults with Parkinson's disease who have a specific GBA1 gene mutation. The main goal is to check safety and tolerability over two years, while also measuring changes in a key biomarker linked to the disease…
Phase: PHASE1, PHASE2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 12:58 UTC
-
Experimental gene therapy hopes to quiet seizures in kids with rare STXBP1 brain disease
Disease control TerminatedThis early-stage trial tests a single dose of CAP-002 gene therapy in 12 children aged 18 months to 8 years with STXBP1 encephalopathy, a genetic condition that causes severe seizures and developmental delays. The main goal is to check safety, but researchers will also track whet…
Phase: PHASE1, PHASE2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 12:57 UTC